DXCM vs LFST: fair value comparison
DexCom, Inc. and LifeStance Health Group, Inc. · Updated 2026-10-19
LFST is still awaiting a full valuation verdict under our six-validated-windows standard. Within Healthcare, DXCM currently ranks higher by quality score.
| DXCM | LFST | |
|---|---|---|
| Verdict | Undervalued | Awaiting full valuation |
| Last price | $84.11 | $11.74 |
| 12-month range | $54.84–$92.34 | $4.81–$13.38 |
| Rank by discount to fair value | #13 of 108 Healthcare | — |
| Rank by quality score | #38 of 301 Healthcare | #40 of 301 Healthcare |
| Quality grade | A | A |
| Leverage | Moderate | Low |
| Margin trend | Expanding | Stable |
| Revenue growth | Strong | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: DXCM fair value analysis · LFST fair value analysis